Integrated BioPharma, Inc. is an early‐stage biopharmaceutical company focused on the research, development and commercialization of cannabinoid-based therapeutics. Trading on the OTC Markets under the symbol INBP, the company leverages proprietary formulations of cannabidiol (CBD) and other active pharmaceutical ingredients to address a variety of unmet medical needs. Integrated BioPharma’s core activities include discovery research, formulation development and preclinical testing in areas such as metabolic disorders, oncology, gastrointestinal disease and chronic pain.
At the heart of Integrated BioPharma’s strategy is a versatile drug‐delivery platform designed to optimize the bioavailability and targeted release of cannabinoid compounds. The company’s pipeline features multiple preclinical candidates, including treatments for type 1 diabetes, lung cancer, irritable bowel syndrome and neuropathic pain. These programs utilize diverse delivery formats—topical, oral, inhalation and ocular—to maximize therapeutic outcomes and patient compliance.
Integrated BioPharma maintains strategic collaborations with academic institutions and contract research organizations across North America and Europe, supporting its R&D efforts and advancing pipeline candidates through toxicology, pharmacokinetics and formulation studies. The company also operates a manufacturing partner network that adheres to current Good Manufacturing Practices (cGMP), enabling scale-up of clinical material and eventual commercial production. Its geographical focus extends to key markets in the United States, Canada and select European territories, with plans for broader global expansion upon regulatory approval.
The leadership team at Integrated BioPharma brings together seasoned executives with decades of experience in pharmaceutical development, clinical operations and regulatory affairs. Under the guidance of its board of directors and senior management, the company continues to refine its clinical strategy, pursue additional partnerships and engage with regulatory authorities to advance its novel cannabinoid therapies toward human trials and, ultimately, market authorization.
AI Generated. May Contain Errors.
